RosVivo Therapeutics

About:

RosVivo Therapeutics is a biotechnology company it develops microRNA-based therapeutics for type 2 diabetes, obesity, fatty liver disease.

Website: https://rosvivo.com/

Description:

RosVivo Therapeutics is a biotechnology company it develops microRNA-based therapeutics for type 2 diabetes, obesity, fatty liver disease. RosVivo Therapeutics targets diseases with breakthrough therapies utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. Discovery research conducted by Dr. Seungil Ro’s laboratory recently identified key miRNAs responsible for the onset and development of Type 2 Diabetes (T2D). Preclinical studies show depletion of these key miRNAs lead to the development of not only T2D, but also obesity, fatty acid liver disease, hyperlipidemia, and gastroparesis. Remarkably, restoration of these miRNAs reverses these disease states.

Total Funding Amount:

$5.45M

Headquarters Location:

Reno, Nevada, United States

Founded Date:

2021-01-01

Contact Email:

sro(AT)rosvivo.com

Founders:

Sandra Poudrier, Seungil Ro

Number of Employees:

1-10

Last Funding Date:

2021-06-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai